Peanut Oral Immunotherapy: a Current Perspective
Autor: | Gerald B. Lee, Meera Patrawala, Jennifer Shih, Brian P. Vickery |
---|---|
Rok vydání: | 2020 |
Předmět: |
Pulmonary and Respiratory Medicine
medicine.medical_specialty Allergy Oral immunotherapy Arachis Peanut allergy medicine.medical_treatment Immunology Administration Oral Desensitization 03 medical and health sciences 0302 clinical medicine Quality of life (healthcare) Food allergy Immunology and Allergy Medicine Humans Peanut Hypersensitivity 030223 otorhinolaryngology Intensive care medicine Desensitization (medicine) business.industry Oral food challenge food and beverages Immunoglobulin E medicine.disease Food Allergy (E Kim Section Editor) Clinical trial Treatment Outcome 030228 respiratory system Desensitization Immunologic Quality of Life Sustained unresponsiveness business |
Zdroj: | Current Allergy and Asthma Reports |
ISSN: | 1534-6315 |
Popis: | Purpose of the Review Peanut oral immunotherapy (OIT) is one of the most studied experimental therapies for food allergy. With the recently FDA-approved peanut product, Palforzia, the goal of this article is to review the most recent data from clinical trials, discuss recent trends, and anticipate future developments. Recent Findings The latest research suggests that peanut OIT could be a promising option for peanut-allergic patients, with the majority of participants in research studies achieving the primary efficacy endpoint of desensitization, as well as sustained unresponsiveness in select populations. Some studies also showed improvements in food allergy-related quality of life. However, peanut OIT is not without risk or side effects, including potentially serious allergic reactions. Summary Future research will need to evaluate the short- and long-term effectiveness of the therapy in the real-world setting, predictors of important treatment outcomes, and the use of adjunctive therapies that may mitigate some of these allergic reactions. |
Databáze: | OpenAIRE |
Externí odkaz: |